Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma
Abstract Aim There is an urgent need to establish biomarkers for the treatment of pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to investigate the usefulness of the combined assessment of carbohydrate antigen 19‐9 (CA19‐9), carcinoembryonic antigen (CEA), and duke pancreatic mon...
Main Authors: | Tadataka Takagi, Minako Nagai, Satoshi Nishiwada, Taichi Terai, Satoshi Yasuda, Yasuko Matsuo, Shunsuke Doi, Yuichiro Kohara, Masayuki Sho |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | Annals of Gastroenterological Surgery |
Subjects: | |
Online Access: | https://doi.org/10.1002/ags3.12629 |
Similar Items
-
Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report
by: Seiji Nakahara, et al.
Published: (2023-08-01) -
Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma
by: Satoshi Yasuda, et al.
Published: (2023-05-01) -
Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
by: Alessandro Coppola, et al.
Published: (2023-05-01) -
Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement
by: Takahiro Akahori, et al.
Published: (2024-01-01) -
A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
by: Lingyu Zhu, et al.
Published: (2023-08-01)